Adaptive Biotechnologies (ADPT) Receivables - Net (2018 - 2026)

Adaptive Biotechnologies has disclosed Receivables - Net across 9 years of filings, most recently posting $48.3 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $48.3 million, up 10.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.3 million (up 10.86% YoY), and the FY2025 annual result was $50.4 million, up 20.69% from the prior year.
• Receivables - Net came in at $48.3 million for Q1 2026 at Adaptive Biotechnologies, down from $50.4 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $50.4 million in Q4 2025 to a low of $22.5 million in Q1 2022.
• The 5-year median for Receivables - Net is $40.1 million (2022), against an average of $37.4 million.
• Across the five-year window, Receivables - Net surged 130.09% in 2022 and dropped 5.21% in 2023, its largest moves.
• Adaptive Biotechnologies' Receivables - Net stood at $40.1 million in 2022, then declined by 5.21% to $38.0 million in 2023, then climbed by 9.91% to $41.7 million in 2024, then rose by 20.69% to $50.4 million in 2025, then fell by 4.07% to $48.3 million in 2026.
• The last three Receivables - Net figures came in at $48.3 million (Q1 2026), $50.4 million (Q4 2025), and $44.8 million (Q3 2025), per Business Quant data.